Clinical Trial Update: Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic and safety study of niraparib in patients with normal or moderate hepatic impairment has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms
• Ovarian Neoplasms
• Solid Tumor

Drugs mentioned

• Niraparib (Niraparib)

Snippet

Sponsor: Tesaro, Inc. | Conditions: Ovarian Neoplasms, Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2020-11-16